BriaCell Therapeutics Corp.
TSX:BCT.TOBiotechnology
+$0.94 today
- Market cap
- $50.02M
- Beta
- 1.53
- P/E (TTM)
- -0.3
- EPS (TTM)
- -$4.23
Volume 0.00M
Average 0.01M
BCT.TO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
BriaCell Therapeutics Corp.TSX: BCT.TO
Cost of Revenue · Q3 FY2026 · quarter ended Apr 2026
Cost of revenue remains negative
Q3 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $26.59K.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $6.65K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 107.93K USD
- Year-over-year change
- —
- 4-year CAGR
- +62.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 107.93K | — |
| FY2024 | 2024-07-31 | 0 | — |
| FY2023 | 2023-07-31 | 0 | — |
| FY2022 | 2022-07-31 | 0 | -100.0% |
| FY2021 | 2021-07-31 | 15.55K | — |
Cost of Revenue vs competitors
How BCT.TO compares with its peers on the latest reported figures
No competitor Cost of Revenue figures are available to compare.
Income Statement
Metric | FY2021 Jul 2021 | FY2022 Jul 2022 | FY2023 Jul 2023 | FY2024 Jul 2024 | FY2025 Jul 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15.55K | 0 | 0 | 0 | 107.93K |
| Gross Profit | (15.55K) | 0 | 0 | 0 | (107.93K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.02M | 8.02M | 15.34M | 27.18M | 21.53M |
| Selling, General & Admin | 4.96M | 7.27M | 7.94M | 6.15M | 5.9M |
| Operating Expenses | 6.97M | 15.29M | 23.27M | 33.33M | 27.43M |
| Depreciation & Amortization | 15.55K | 15.27K | 15.27K | 83.9K | 107.93K |
| EBITDA | (7.1M) | (26.82M) | (23.26M) | (4.85M) | (27.43M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.11M) | (15.29M) | (23.27M) | (33.33M) | (27.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.21K | 136.73K | 891.21K | 288.02K | 121.42K |
| Interest Expense | 80.09K | 979 | 0 | 0 | 37.43K |
| Other Income / Expenses | (6.84M) | (11.55M) | 2.97M | 28.4M | 656.6K |
| Income Before Tax | (13.82M) | (26.84M) | (20.3M) | (4.93M) | (26.88M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.82M) | (26.84M) | (20.3M) | (4.79M) | (26.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (467.51) | (259.50) | (195.00) | (43.68) | (62.95) |
| EPS (Diluted) | (467.51) | (259.50) | (195.00) | (43.68) | (62.95) |
| Weighted Avg Shares | 30.13K | 103.29K | 104.13K | 109.7K | 423.11K |
| Weighted Avg Shares (Diluted) | 30.13K | 103.29K | 104.13K | 109.7K | 423.11K |
BriaCell Therapeutics Corp.
TSX:BCT.TO
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.